NCT05726916View on ClinicalTrials.gov

Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome

PHASE3RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 9, 2023

Primary Completion Date

May 9, 2026

Study Completion Date

November 9, 2027

Conditions
Hypertensive Emergency-associated Hemolytic Uremic Syndrome
Interventions
DRUG

Soliris®

Eculizumab IV administration (900mg/w during 4w then 1200 mg at w5 and 1200mg/2w for 8w) + Blood pressure control with renin angiotensin system blockers

DRUG

Renin angiotensin system blockers

Blood pressure control with renin angiotensin system blockers

Trial Locations (1)

75020

RECRUITING

Tenon Hospital, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER